Effects of exenatide on diabetes, obesity, cardiovascular risk factors, and hepatic biomarkers in patients with type 2 diabetes

Journal of Diabetes Science and Technology

Volumn 2, Issue 2, 2008, Pages 255-260

  Nielsen, Loretta L ^a   Okerson, Ted ^a   Holcombe, John ^b   Hoogwerf, Byron ^c  

^a AMYLIN PHARMACEUTICALS INC   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Exenatide; NAFLD; Obesity; Type 2 diabetes

Indexed keywords

EID: 67649373364     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/193229680800200214     Document Type: Review

References (37)

1. Anderson JW, Kendall CW, Jenkins DJ. Importance of weight management in type 2 diabetes: review with meta-analysis of clinical studies. J Am Coll Nutr. 2003;22(5):331-9.
2. Maggio CA, Pi-Sunyer FX. Obesity and type 2 diabetes. Endocrinol Metab Clin North Am. 2003;32(4):805-22.
3. Stein CJ, Colditz GA. The epidemic of obesity. J Clin Endocrinol Metab. 2004;89(6):2522-5.
4. Mokdad AH, Ford ES, Bowman BA, Nelson DE, Engelgau MM, Vinicor F, Marks JS. Diabetes trends in the U. S.: 1990-1998. Diabetes Care. 2000;23(9):1278-83.
5. Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, Marks JS. Prevalence of obesity, diabetes, and obesityrelated health risk factors, 2001. JAMA. 2003;289(1):76-9.
6. Bray GA. Medical consequences of obesity. J Clin Endocrinol Metab. 2004;89(6):2583-9.
7. Yki-Järvinen H, Westerbacka J. The fatty liver and insulin resistance. Curr Mol Med. 2005;5(3):287-95.
8. Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, Eckel R, Fonseca V, Gerstein HC, Grundy S, Nesto RW, Pignone MP, Plutzky J, Porte D, Redberg R, Stitzel KF, Stone NJ. Primary prevention of cardiovascular diseases in people with diabetes mellitus. Diabetes Care. 2007;30(1):162-72.
9. Stonehouse AH, Maggs DG. Emerging therapies for type 2 diabetes. Curr Drug Ther. 2007;2:151-60.
10. U. K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U. K. Prospective Diabetes Study Group. Diabetes. 1995;44(11):1249 58.
11. Purnell JQ, Weyer C. Weight effect of current and experimental drugs for diabetes mellitus: from prevention to alleviation of obesity.. Treat Endocrinol. 2003;2(1):33-47.
12. Williamson DF, Thompson TJ, Thun M, Flanders D, Pamuk E, Byers T. Intentional weight loss and mortality among overweight individuals with diabetes. Diabetes Care. 2000;23(10):1499-504.
13. American Gastroenterological Association medical position statement: nonalcoholic fatty liver disease.. Gastroenterology. 2002;123(5):1702-4.
14. Raz I, Eldor R, Cernea S, Shafrir E. Diabetes: insulin resistance and derangements in lipid metabolism. Cure through intervention in fat transport and storage. Diabetes Metab Res Rev. 2005;21(1):3-14.
15. Targher G, Bertolini L, Padovani R, Rodella S, Tessari R, Zenari L, Day C, Arcaro G. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients.. Diabetes Care. 2007;30(5):1212-8.
16. Eng J, Kleinman WA, Singh L, Singh G, Raufman JP. Isolation and characterization of exendin-4, an exendin-3 analogue from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem. 1992;267(11):7402-5.
17. Young AA. Glucagon-like peptide-1, exendin and insulin sensitivity. In: Hansen B, Shafrir E, editors. Insulin resistance and insulin resistance syndrome. New York: Harwood Academic Press; 2002. p. 235-62.
18. Parkes DG, Pittner R, Jodka C, Smith P, Young A. Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro. Metabolism. 2001;50(5):583-9.
19. Webb DM, Wintle M, Malone JK. Exenatide effects on glucose metabolism and metabolic disorders common to overweight and obese patients with type 2 diabetes.. Drug Dev Res. 2006;67(8):666-76.
20. Nauck MA, Duran S, Kim D, Johns D, Northrup J, Festa A, Brodows R, Trautmann M. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study.. Diabetologia. 2007;50(2):259-67.
21. Zinman B, Hoogwerf BJ, Garcia SD, Milton DR, Giaconia JM, Kim DD, Trautmann ME, Brodows RG. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes. Ann Intern Med. 2007;146(7):477-85.
22. Mack C, Laugero K, Liu Q, Jodka C, Young A, Parkes D. Therapeutic applications of incretin mimetics for metabolic diseases: preclinical studies. Drug Dev Res. 2006;67(7):553-8.
23. Chen YE, Drucker DJ. Tissue-specific expression of unique mRNAs that encode proglucagon-derived peptides or exendin 4 in the lizard.. J Biol Chem. 1997;272(7):4108-15.
24. Kolterman OG, Kim DD, Shen L, Ruggles JA, Nielsen LL, Fineman MS, Baron AD. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus.. Am J Health Syst Pharm. 2005;62(2):173-81.
25. Fehse F, Trautmann M, Holst JJ, Halseth AE, Nanayakkara N, Nielsen LL, Fineman MS, Kim DD, Nauck MA. Exenatide augments frst- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes.. J Clin Endocr Metab. 2005;90(11):5991-7.
26. Nielsen LL, Young AA, Parkes D. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes.. Regul Pept. 2004;117(2):77-88.
27. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes.. Diabetes Care. 2004;27(11):2628-35.
28. De Fronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes.. Diabetes Care. 2005;28(5):1092-100.
29. Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea.. Diabetes Care. 2005;28(5):1083-91.
30. Blonde L, Klein EJ, Han J, Zhang B, MacSM, Poon TH, Taylor KL, Trautmann ME, Kim DD, Kendall DM. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes.. Diabetes Obes Metab. 2006;8(4):436-47.
31. Buse JB, Klonoff DC, Nielsen LL, Guan X, Bowlus CL, Holcombe JH, Maggs DG, Wintle ME. Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three doubleblind, placebo-controlled trials.. Clin Ther. 2007;29(1):139-53.
32. Klonoff DC, Buse JB, Nielsen LL, Guan X, Bowlus CL, Holcombe JH, Wintle ME, Maggs DG. Exenatide effects on diabetes, obesity, cardiovascular risk factors, and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years.. Curr Med Res Opin. 2008;24(1):275-86.
33. Tushuizen ME, Bunck MC, Pouwels PJ, Van Waesberghe JH, Diamant M, Heine RJ. Incretin mimetics as a novel therapeutic option for hepatic steatosis. Liver Int. 2006;26(8):1015-7.
34. Ding X, Saxena NK, Lin S, Gupta N, Anania FA. Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice.. Hepatology. 2006;43(1):173-81.
35. Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG; GWAA Study Group. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes. Ann Intern Med. 2005;143(8):559-569.
36. Kim D, MacConell L, Zhuang D, Kothare PA, Trautmann M, Fineman M, Taylor K. Effects of once-weekly dosing of a longacting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes.. Diabetes Care. 2007;30(6):1487-93.
37. Nelson P, Poon T, Guan X, Schnabel CA, Wintle M, Fineman M. The incretin mimetic exenatide as a monotherapy in patients with type 2 diabetes. Diabetes Technol Ther. 2007;9(4):317-26.